A team of scientists at the University of Sydney has recorded a breakthrough in the search for more effective treatments for Parkinson’s disease, raising hope for millions affected by the degenerative neurological disorder.

The researchers identified a malfunctioning form of the SOD1 protein as a contributing factor in the onset of Parkinson’s symptoms. In a controlled study involving mice, the team reported that administering a copper-based compound targeting the faulty protein significantly improved motor function, an outcome that could pave the way for novel therapeutic interventions.

Lead researcher on the study, Prof. Kay Double, described the findings as a promising step forward in the fight against the disease. “We were astonished by the success of the intervention,” she said. “The results suggest that this treatment approach could slow the progression of Parkinson’s disease in humans.”

Parkinson’s disease affects millions globally and is marked by tremors, muscle rigidity, and impaired balance. Current treatment options are largely limited to managing symptoms rather than addressing underlying causes. The study’s outcome represents a shift in focus toward potential disease-modifying therapies.

Researchers said the next phase of the work will focus on determining the most effective and safe method of targeting the dysfunctional SOD1 protein in clinical settings. Plans are underway to prepare for human trials.

Experts have welcomed the findings as further evidence of the importance of sustained investment in neurological research. If successful in humans, the therapy could offer a vital new tool in slowing or even halting the progression of Parkinson’s disease.